Jagsonpal Pharmaceuticals Reports Strong Q3 FY24-25 Results with Record Profit and Sales Growth
Jagsonpal Pharmaceuticals reported its third-quarter financial results for FY24-25, revealing a Profit After Tax of Rs 12.81 crore, the highest in five quarters. Net sales reached Rs 74.03 crore, indicating significant growth compared to previous quarters, reflecting a positive trend in the company's financial performance.
Jagsonpal Pharmaceuticals has recently announced its financial results for the third quarter of FY24-25, with the report released on January 22, 2025. The company achieved a Profit After Tax (PAT) of Rs 12.81 crore, which is a notable increase compared to the average PAT of Rs 6.69 crore over the preceding four quarters. This PAT figure is the highest recorded by Jagsonpal Pharmaceuticals in the last five quarters, suggesting a favorable trend in its financial performance.In terms of net sales, the company reported Rs 74.03 crore for the quarter, which represents a substantial growth relative to the average net sales of Rs 56.71 crore from the previous four quarters. This sales performance reinforces the positive trajectory observed in the company's financial results.
Additionally, there has been an adjustment in the evaluation of Jagsonpal Pharmaceuticals, with its performance score reflecting a revision to 21 from 18 over the last three months. This change indicates a favorable outlook based on the financial data available as of December 2024.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
